{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:42:00Z","timestamp":1740120120793,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12185-023-03664-1","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T15:04:06Z","timestamp":1695222246000},"page":"711-717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of previous anthracycline therapy in patients with acute myeloid leukemia receiving venetoclax"],"prefix":"10.1007","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0324-898X","authenticated-orcid":false,"given":"Ryujiro","family":"Hara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norisato","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ogiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetsugu","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawako","family":"Shiraiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"3664_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138. https:\/\/doi.org\/10.1038\/nm.3048.","journal-title":"Nat Med"},{"key":"3664_CR2","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, Dinardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345. https:\/\/doi.org\/10.1182\/blood.2020004856.","journal-title":"Blood"},{"key":"3664_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD Dinardo","year":"2020","unstructured":"Dinardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"key":"3664_CR4","doi-asserted-by":"publisher","first-page":"649209","DOI":"10.3389\/fonc.2021.649209","volume":"11","author":"ME Tenold","year":"2021","unstructured":"Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, Abedi M, et al. Outcomes of adults with relapsed\/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a Comprehensive Cancer Center. Front Oncol. 2021;11:649209. https:\/\/doi.org\/10.3389\/fonc.2021.649209.","journal-title":"Front Oncol"},{"key":"3664_CR5","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 2021;5:1552\u201364. https:\/\/doi.org\/10.1182\/bloodadvances.2020003734.","journal-title":"Blood Adv"},{"key":"3664_CR6","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/ajh.25978","volume":"95","author":"E Morsia","year":"2020","unstructured":"Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95:1511\u201321. https:\/\/doi.org\/10.1002\/ajh.25978.","journal-title":"Am J Hematol"},{"key":"3664_CR7","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol. 2019;37:1277\u201384. https:\/\/doi.org\/10.1200\/JCO.18.01600.","journal-title":"J Clin Oncol"},{"key":"3664_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD Dinardo","year":"2020","unstructured":"Dinardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803. https:\/\/doi.org\/10.1182\/blood.2019003988.","journal-title":"Blood"},{"key":"3664_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"3664_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/(sici)1097-0320(19990601)36:2<140::aid-cyto8>3.0.co;2-p","volume":"36","author":"F Durrieu","year":"1999","unstructured":"Durrieu F, Belaud-Rotureau MA, Lacombe F, Dumain P, Reiffers J, Boisseau MR, et al. Synthesis of Bcl-2 in response to anthracycline treatment may contribute to an apoptosis-resistant phenotype in leukemic cell lines. Cytometry. 1999;36:140\u20139. https:\/\/doi.org\/10.1002\/(sici)1097-0320(19990601)36:2%3c140::aid-cyto8%3e3.0.co;2-p.","journal-title":"Cytometry"},{"key":"3664_CR11","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1038\/sj.leu.2401571","volume":"13","author":"V Nuessler","year":"1999","unstructured":"Nuessler V, St\u00f6tzer O, Gullis E, Pelka-Fleischer R, Pogrebniak A, Gieseler F, et al. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines. Leukemia. 1999;13:1864\u201372. https:\/\/doi.org\/10.1038\/sj.leu.2401571.","journal-title":"Leukemia"},{"key":"3664_CR12","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1038\/sj.onc.1201023","volume":"14","author":"M Allouche","year":"1997","unstructured":"Allouche M, Bettaieb A, Vindis C, Rousse A, Grignon C, Laurent G. Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. Oncogene. 1997;14:1837\u201345. https:\/\/doi.org\/10.1038\/sj.onc.1201023.","journal-title":"Oncogene"},{"key":"3664_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362\u201375. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0609.","journal-title":"Cancer Discov"},{"key":"3664_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/leu.2014.1","volume":"28","author":"SL Khaw","year":"2014","unstructured":"Khaw SL, M\u00e9rino D, Anderson MA, Glaser SP, Bouillet P, Roberts AW, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014;28:1207\u201315. https:\/\/doi.org\/10.1038\/leu.2014.1.","journal-title":"Leukemia"},{"key":"3664_CR15","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.3324\/haematol.2021.278506","volume":"106","author":"N Osada","year":"2021","unstructured":"Osada N, Kikuchi J, Koyama D, Kuroda Y, Yasui H, Leverson JD, et al. mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation. Haematologica. 2021;106:3008\u201313. https:\/\/doi.org\/10.3324\/haematol.2021.278506.","journal-title":"Haematologica"},{"key":"3664_CR16","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood.2021014241","volume":"140","author":"M Janssen","year":"2022","unstructured":"Janssen M, Schmidt C, Bruch PM, Blank MF, Rohde C, Waclawiczek A, et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. Blood. 2022;140:2594\u2013610. https:\/\/doi.org\/10.1182\/blood.2021014241.","journal-title":"Blood"},{"key":"3664_CR17","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1182\/blood.2022017344","volume":"140","author":"T Braun","year":"2022","unstructured":"Braun T. An unexpected partnership targeting FLT3wt AML. Blood. 2022;140:2529\u201330. https:\/\/doi.org\/10.1182\/blood.2022017344.","journal-title":"Blood"},{"key":"3664_CR18","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1080\/10428194.2020.1761964","volume":"61","author":"C Ganzel","year":"2020","unstructured":"Ganzel C, Ram R, Gural A, Wolach O, Gino-Moor S, Vainstein V, et al. Venetoclax is safe and efficacious in relapsed\/refractory AML. Leuk Lymphoma. 2020;61:2221\u20135. https:\/\/doi.org\/10.1080\/10428194.2020.1761964.","journal-title":"Leuk Lymphoma"},{"key":"3664_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD Dinardo","year":"2018","unstructured":"Dinardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93:401\u20137. https:\/\/doi.org\/10.1002\/ajh.25000.","journal-title":"Am J Hematol"},{"key":"3664_CR20","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica. 2018;103:e404\u20137. https:\/\/doi.org\/10.3324\/haematol.2018.188094.","journal-title":"Haematologica"},{"key":"3664_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00277-020-04321-x","volume":"100","author":"E Schuler","year":"2021","unstructured":"Schuler E, Wagner-Drouet EM, Ajib S, Bug G, Crysandt M, Dressler S, et al. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol. 2021;100:959\u201368. https:\/\/doi.org\/10.1007\/s00277-020-04321-x.","journal-title":"Ann Hematol"},{"key":"3664_CR22","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1111\/cas.15048","volume":"112","author":"Y Wei","year":"2021","unstructured":"Wei Y, Xiong X, Li X, Lu W, He X, Jin X, et al. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci. 2021;112:3636\u201344. https:\/\/doi.org\/10.1111\/cas.15048.","journal-title":"Cancer Sci"},{"key":"3664_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021;96:208\u201317. https:\/\/doi.org\/10.1002\/ajh.26039.","journal-title":"Am J Hematol"},{"key":"3664_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13581","author":"G Weng","year":"2022","unstructured":"Weng G, Zhang Y, Yu G, Luo T, Yu S, Xu N, et al. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia. J Intern Med. 2022. https:\/\/doi.org\/10.1111\/joim.13581.","journal-title":"J Intern Med"},{"key":"3664_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14082025","author":"S Garciaz","year":"2022","unstructured":"Garciaz S, Hospital MA, Alary AS, Saillard C, Hicheri Y, Mohty B, et al. Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14082025.","journal-title":"Cancers (Basel)"},{"key":"3664_CR26","doi-asserted-by":"publisher","first-page":"106803","DOI":"10.1016\/j.leukres.2022.106803","volume":"114","author":"E De Bellis","year":"2022","unstructured":"De Bellis E, Imbergamo S, Candoni A, Li\u00e7o A, Tanasi I, Mauro E, et al. Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: A real-life multicenter experience. Leuk Res. 2022;114:106803. https:\/\/doi.org\/10.1016\/j.leukres.2022.106803.","journal-title":"Leuk Res"},{"key":"3664_CR27","doi-asserted-by":"publisher","first-page":"6557","DOI":"10.26355\/eurrev_202111_27126","volume":"25","author":"MA Ucar","year":"2021","unstructured":"Ucar MA, Ozet G, Koyuncu MB, Sonmez M, Akidan O, Ayli M, et al. Real world results of venetoclax combined with hypomethylating agents in relapsed\/refractory AML. Eur Rev Med Pharmacol Sci. 2021;25:6557\u201365. https:\/\/doi.org\/10.26355\/eurrev_202111_27126.","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03664-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03664-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03664-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T15:13:28Z","timestamp":1700838808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03664-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3664"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03664-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}